Article

Implications of alternative definitions of prediabetes for prevalence in U.S. adults.

RTI International, Atlanta Regional Office, Atlanta, Georgia, USA.
Diabetes care (Impact Factor: 8.57). 02/2011; 34(2):387-91. DOI: 10.2337/dc10-1314
Source: PubMed

ABSTRACT To compare the prevalence of prediabetes using A1C, fasting plasma glucose (FPG), and oral glucose tolerance test (OGTT) criteria, and to examine the degree of agreement between the measures.
We used the 2005-2008 National Health and Nutrition Examination Surveys to classify 3,627 adults aged ≥ 18 years without diabetes according to their prediabetes status using A1C, FPG, and OGTT. We compared the prevalence of prediabetes according to different measures and used conditional probabilities to examine agreement between measures.
In 2005-2008, the crude prevalence of prediabetes in adults aged ≥ 18 years was 14.2% for A1C 5.7-6.4% (A1C5.7), 26.2% for FPG 100-125 mg/dL (IFG100), 7.0% for FPG 110-125 mg/dL (IFG110), and 13.7% for OGTT 140-199 mg/dL (IGT). Prediabetes prevalence varied by age, sex, and race/ethnicity, and there was considerable discordance between measures of prediabetes. Among those with IGT, 58.2, 23.4, and 32.3% had IFG100, IFG110, and A1C5.7, respectively, and 67.1% had the combination of either A1C5.7 or IFG100.
The prevalence of prediabetes varied by the indicator used to measure risk; there was considerable discordance between indicators and the characteristics of individuals with prediabetes. Programs to prevent diabetes may need to consider issues of equity, resources, need, and efficiency in targeting their efforts.

3 Followers
 · 
164 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: In 2010, the American Diabetes Association recommended that individuals with hemoglobin A1c 5.7-6.4% be classified as prediabetic even in the absence of impaired fasting glucose (IFG). AIM OF STUDY: To compare the clinical and metabolic characteristics of patients receiving antipsychotic drugs who have normal glucose tolerance (NGT), hemoglobin A1c 5.7-6.4% or IFG (fasting glucose 100-125mg/dL). METHOD: Body mass index, waist circumference, fasting glucose, insulin, lipids, hemoglobin A1c, and insulin resistance assessed with the homeostatic model (HOMA-IR) were measured in a consecutive cohort of adult psychiatric inpatients with NGT (N=423), hemoglobin A1c 5.7-6.4% (N=130), IFG (N=52) and IFG plus hemoglobin A1c 5.7-6.4% (n=39). RESULTS: The hemoglobin A1c 5.7-6.4% group had lower fasting insulin levels (9.8±5.6 vs. 15.5±11.4μU/mL, p<0.0001) and HOMA-IR (2.1±1.2 vs. 4.1±3.1, p<0.0001) than the IFG group, but were metabolically similar to those with NGT. The hemoglobin A1c 5.7-6.4% was the predominant prediabetic pattern in patients treated with antipsychotics other than clozapine or olanzapine. Patients with hemoglobin A1c 5.7-6.4% and those with IFG were statistically similar in age (40.1±13.6 vs. 39.7±10.3 years), body mass index (26.0±4.8 vs. 26.3±4.9) and waist circumference 93.1±13.9 vs. 98.1±12.1cm for males and 92.5±13.5 vs. 90.7±15.8cm for females. CONCLUSION: The hemoglobin A1c in the 5.7-6.4% range is common in euglycemic patients receiving antipsychotic drugs and this prediabetic pattern has metabolic and pharmacological features that differentiates it from IFG.
    European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 05/2012; 23(3). DOI:10.1016/j.euroneuro.2012.05.002 · 5.40 Impact Factor
  • Source
    Investigative ophthalmology & visual science 05/2011; 52(6):3593; author reply 3594. DOI:10.1167/iovs.11-7312 · 3.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Type 2 diabetes is a chronic, debilitating and often deadly disease that has reached epidemic proportions. The onset of diabetes can be delayed or prevented in high-risk individuals by diet and lifestyle changes and medications, and hence a key element for addressing the diabetes epidemic is to identify those most at risk of developing diabetes so that preventative measures can be effectively focused. The PreDx(®) Diabetes Risk Score is a multimarker tool for assessing a patient's risk of developing diabetes within the next 5 years. Requiring a simple blood draw using standard sample collection and handling procedures, the PreDx Diabetes Risk Score is easily implemented in clinical practice and provides an assessment of diabetes risk that is superior to other measures, including fasting plasma glucose, glycated hemoglobin, measures of insulin resistance and other clinical measures. In this article, we provide an overview of the PreDx Diabetes Risk Score.
    Expert Review of Molecular Diagnostics 11/2011; 11(8):775-92. DOI:10.1586/erm.11.63 · 4.27 Impact Factor

Preview (2 Sources)

Download
1 Download
Available from